AstraZeneca’s Imfinzi has scored another Phase III hit, this time in limited-stage small cell lung cancer (LS-SCLC), putting it on course to be the first immunotherapy approved in the setting.
The ADRIATIC trial of Imfinzi (durvalumab) bolsters AstraZeneca’s goal to treat more lung cancer patients in early disease stages and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?